Are Pharmaceuticals Poised for a Rebound? The Key Metric to Keep in Mind With pharmaceutical M&A ramping up and robust pipelines with high impact launches on the horizon, investors may be considering renewed exposure to this subset of Health Care stocks. However, those focused on free cash flow (FCF) metrics may have already identified opportunities in the sector. VictoryShares Free Cash Flow ETF (VFLO)currently offers exposure to this area of the market that could be worth consideration. VFLO's top holding ...

Merck will have the exclusive right to develop and commercialize antibody candidates that come out of the collaboration. Infinimmune said it will use its proprietary platform to screen large numbers of human immune cells and identify naturally occurring antibodies, then use AI tools to refine and improve them. The companies did not disclose the disease targets Merck selected for the partnership. Infinimmune, Merck enter into antibody discovery pact | Reuters Exclusive news, data and analytics for financial ...

Merck's drug reduced bad cholesterol by 64.6% in late-stage trial | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Financecategory· March 30, 2026 · 3:45 PM UTC · ago Federal Reserve Chair Jerome Powell said on Monday the U.S. central bank is watching developments in the private credit sector for signs of trouble, but does not currently see issues there bringing down the financial system as a whole. The Merck logo is seen at a gate to the Merck & Co ca ...

The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) has a very simple strategy. It tracks an index that aims to hold the top 100 high-yielding dividend stocks. That index reshuffles its holdings once a year to ensure it contains only the best of the best. The fund recently completed its annual reconstitution. One of the more notable changes was an increase in its allocation to high-yielding dividend stocks in the healthcare sector. Here's a closer look at some of the fund's recent changes. Will AI create t ...

If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Towards the end of the first quarter, Merck ( MRK ) announced a larger acquisition to ignite some appeal in its pipeline. This was the second-largest deal announced in recent times, as Merck is sp ...

Jim Cramer reviewed Pfizer Inc. (NYSE:PFE) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Cramer mentioned the stock during the episode and said: In a slowdown, the hedge fund playbook says you want safety stocks. The stocks of companies that will make good money even if the broader economy deteriorates dramatically, the opposite of cyclical stocks. For example, big pharma. Now, if you need a medication, you’ll keep taking it in good times and bad. You don’t ...

Key Takeaways J&J's Innovative Medicine unit is expected to post Q1 growth despite Stelara LOE impactJNJ's growth likely driven by Darzalex, Tremfya, Erleada and the uptake of newer therapies like CarvyktiJNJ faces pressure from Stelara biosimilars, Imbruvica decline and Part D redesign headwindsJohnson & Johnson (JNJ) , via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, ...

Key Takeaways Merck will acquire Terns Pharma for $6.7B, adding leukemia candidate TERN-701 to its pipeline.MRK's recent deals span oncology, immunology, and antivirals to reduce heavy Keytruda reliance.Keytruda drives over half of MRK pharma sales, with LOE in 2028 pushing the need for new growth drivers.Merck (MRK) has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, particularly in oncology and immunology. The company’s recent deals reflect a ...

Key Takeaways Merck stock jumped 51.4% in six months, driven by optimism around post-Keytruda growth prospectsMRK is boosting its pipeline via M&A and new drugs like Winrevair and Capvaxive, gaining tractionMRK faces headwinds from Gardasil declines, generics, and Keytruda patent expiry by 2028Merck’s (MRK) stock has risen 51.4% in the past six months. A key driver of the increase is Merck’s improved outlook for long-term growth once its blockbuster drug, Keytruda, loses patent exclusivity. Keytruda, approv ...

Key Takeaways Tempus AI expands 2026 footprint via collaborations across pharma, healthcare, and tech sectors. TEM partners with Daiichi Sankyo to advance oncology ADC program using PRISM2 AI models. Tempus AI integrates Median tech and teams up with NYU Langone to enhance diagnostics and cancer care. Tempus AI (TEM) continues to expand its footprint in 2026 through a series of strategic collaborations. By partnering with leading pharmaceutical companies, healthcare institutions, and technology innovators, ...